Profiles of Deceased Patients with Coronavirus Disease 2019 (COVID-19) and Multidrug-Resistant Bacterial Coinfections at an Indonesian Tertiary Hospital
Downloads
Introduction: Antibiotic use in coronavirus disease 2019 (COVID-19) patients reached 70% during the pandemic, potentially inducing the invasion of multidrug-resistant organisms (MDROs). This study analyzed patients who died from COVID-19 with MDRO coinfections at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Methods: We conducted a retrospective descriptive study of 120 deceased COVID-19 inpatients from January to December 2021. The inclusion criteria required: (1) positive MDRO cultures from ≥2 specimens, and (2) resistance to ≥1 agent across ≥3 antimicrobial categories. Patients with incomplete records or no antibiotic therapy were excluded. The data were presented using descriptive statistics to characterize patient demographics, microbiological profiles, and antimicrobial resistance patterns.
Results: The patients were predominantly male (60%), aged 41–80 years (78.33%), and hospitalized for 8–30 days (53.44%). The microbiological examinations revealed blood cultures as the main specimen source (43.10%), followed by sputum (27.59%), urine (19.40%), pus (7.33%), and cerebrospinal fluid (2.59%). The prevalent isolates varied by specimen type: coagulase-negative staphylococci (51%) in blood, Pseudomonas spp. in pus (17.65%), Klebsiella spp. in sputum (26.69%), and Escherichia coli in urine (37.78%). The cerebrospinal fluid cultures showed an equal distribution of Gram-negative bacilli, Gram-positive bacilli, and Gram-positive cocci (33.33% each).
Conclusion: This study characterizes the profiles of fatal COVID-19 cases with MDRO coinfections, demonstrating a predominance of older male patients with prolonged hospitalization. The identified resistance patterns and pathogen distribution, notably coagulase-negative staphylococci in blood, highlight the importance of improved infection surveillance and antibiotic stewardship to minimize the risk of coinfection in the future.
Highlights:
1. While existing studies have examined multidrug-resistant organism (MDRO) coinfections in COVID-19 globally, this work offers a valuable standalone characterization of a high-risk subgroup in Indonesia, where resistance patterns arising from antimicrobial use during the pandemic created unique clinical challenges.
2. This study provides comprehensive data on the mortality of COVID-19 patients with MDRO coinfections at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia, enhancing medical personnel's awareness of MDRO bacterial transmission and informing improvements in antibiotic stewardship programs within hospitals.
Ankurita B (2023). Role of diagnostic procedures in managing human bacterial infections: A comprehensive overview. Archives of Hematology Case Reports and Reviews 8(1): 008–019. doi: 10.17352/ahcrr.000043.
Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, et al. (2021). The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya. F1000Research 10: 113. doi: 10.12688/f1000research.31645.2.
Catalano A, Iacopetta D, Ceramella J, Pellegrino M, Giuzio F, et al. (2023). Antibiotic-resistant ESKAPE pathogens and COVID-19: The pandemic beyond the pandemic. Viruses 15(9): 1843. doi: 10.3390/v15091843.
Chen X, Liao B, Cheng L, Peng X, Xu X, et al. (2020). The microbial coinfection in COVID-19. Applied Microbiology and Biotechnology 104(18): 7777–7785. doi: 10.1007/s00253-020-10814-6.
Cheng LSK, Chau SKY, Tso EYK, Tsang SWC, Li IYF, et al. (2020). Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: Experience from a single hospital cluster. Therapeutic Advances in Infectious Disease 7. doi: 10.1177/2049936120978095.
Cohen R, Babushkin F, Finn T, Geller K, Alexander H, et al. (2021). High rates of bacterial pulmonary co-infections and superinfections identified by multiplex PCR among critically ill COVID-19 patients. Microorganisms 9(12): 2483. doi: 10.3390/microorganisms9122483.
Greco R, Panetta V, Della Rocca MT, Durante A, Di Caprio G, et al. (2022). Profile of co-infection prevalence and antibiotics use among COVID-19 patients. Pathogens 11(11): 1250. doi: 10.3390/pathogens11111250.
Hagan T, Cortese M, Rouphael N, Boudreau C, Linde C, et al. (2019). Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. Cell 178(6): 1313-1328.e13. doi: 10.1016/j.cell.2019.08.010.
Hoque MN, Akter S, Mishu ID, Islam MR, Rahman MS, et al. (2021). Microbial co-infections in COVID-19: Associated microbiota and underlying mechanisms of pathogenesis. Microbial Pathogenesis 156: 104941. doi: 10.1016/j.micpath.2021.104941.
IBM Corp. (2017). Armonk, NY: IBM SPSS Statistics for Windows, version 25.0. IBM Corp. Retrieved from https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-25.
Indrasari DD, Koendhori EB, Kuntaman K (2022). Impact of the COVID-19 pandemic on antimicrobial resistance at Dr. Soetomo Academic Hospital of Surabaya. International Journal of Health Sciences 6(S6): 1058–1072. doi: 10.53730/ijhs.v6nS6.10535.
Kalluru S, Eggers S, Barker A, Shirley D, Sethi AK, et al. (2018). Risk factors for infection with multidrug-resistant organisms in Haryana, India. American Journal of Infection Control 46(3): 341–345. doi: 10.1016/j.ajic.2017.08.021.
Langford BJ, So M, Raybardhan S, Leung V, Westwood D, et al. (2020). Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clinical Microbiology and Infection 26(12): 1622–1629. doi: 10.1016/j.cmi.2020.07.01.
Larsson DGJ, Flach CF (2022). Antibiotic resistance in the environment. Nature Reviews Microbiology 20(5): 257–269. doi: 10.1038/s41579-021-00649-x.
Mancuso G, Midiri A, Gerace E, Biondo C (2021). Bacterial antibiotic resistance: The most critical pathogens. Pathogens 10(10): 1310. doi: 10.3390/pathogens10101310.
Mangioni D, Chatenoud L, Colombo J, Palomba E, Guerrero FA, et al. (2023). Multidrug-resistant bacterial colonization and infections in large retrospective cohort of mechanically ventilated COVID-19 patients. Emerging Infectious Diseases 29(8): 1598–1607. doi: 10.3201/eid2908.230115.
Michels R, Last K, Becker SL, Papan C (2021). Update on coagulase-negative staphylococci—What the clinician should know. Microorganisms 9(4): 830. doi: 10.3390/microorganisms9040830.
Ministry of Health of the Republic of Indonesia (2021). Peraturan Menteri Kesehatan nomor 28 tahun 2021 tentang pedoman penggunaan antibiotik. Retrieved from https://farmalkes.kemkes.go.id/unduh/permenkes-28-2021/.
Mirzaei R, Goodarzi P, Asadi M, Soltani A, Aljanabi HAA, et al. (2020). Bacterial co-infections with SARS-CoV-2. IUBMB Life 72(10): 2097–2111. doi: 10.1002/iub.2356.
Pletz M, Eckmann C, Hagel S, Heppner H, Huber K, et al. (2015). Multiresistente erreger – Infektionsmanagement 2015. DMW - Deutsche Medizinische Wochenschrift 140(13): 975–981. doi: 10.1055/s-0041-102452.
Santajit S, Indrawattana N (2016). Mechanisms of antimicrobial resistance in ESKAPE pathogens. BioMed Research International 2016: 1–8. doi: 10.1155/2016/2475067.
Słabisz N, Dudek-Wicher R, Leśnik P, Majda J, Kujawa K, et al. (2023). Impact of the COVID-19 pandemic on the epidemiology of bloodstream infections in hospitalized patients—Experience from a 4th military clinical hospital in Poland. Journal of Clinical Medicine 12(18): 5942. doi: 10.3390/jcm12185942.
Son HJ, Kim T, Lee EJ, Park SY, Yu SA, et al. (2021). Risk factors for isolation of multi-drug resistant organisms in coronavirus disease 2019 pneumonia: A multicenter study. American Journal of Infection Control 49(10): 1256–1261. doi: 10.1016/j.ajic.2021.06.005.
Sy CL, Chen PY, Cheng CW, Huang LJ, Wang CH, et al. (2022). Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. Journal of Microbiology, Immunology and Infection 55(3): 359–386. doi: 10.1016/j.jmii.2022.02.001.
Tiri B, Sensi E, Marsiliani V, Cantarini M, Priante G, et al. (2020). Antimicrobial stewardship program, COVID-19, and infection control: Spread of carbapenem-resistant Klebsiella pneumoniae colonization in ICU COVID-19 patients. What did not work? Journal of Clinical Medicine 9(9): 2744. doi: 10.3390/jcm9092744.
U.S. Centers for Disease Control and Prevention (2024). Multidrug-resistant organisms (MDRO) management guidelines. Retrieved from https://www.cdc.gov/infection-control/hcp/mdro-management/index.html.
U.S. Centers for Disease Control and Prevention (2025). Symptoms of COVID-19. Retrieved from https://www.cdc.gov/covid/signs-symptoms/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
Wong SC, Chau PH, So SYC, Chiu KHY, Yuen LLH, et al. (2023). Epidemiology of multidrug-resistant organisms before and during COVID-19 in Hong Kong. Infection Prevention in Practice 5(2): 100286. doi: 10.1016/j.infpip.2023.100286.
World Health Organization (2022). WHO COVID-19 dashboard. Retrieved from https://data.who.int/dashboards/covid19/cases.
Zhang DD, Acree ME, Ridgway JP, Shah N, Hazra A, et al. (2021). Characterizing coinfection in children with COVID-19: A dual center retrospective analysis. Infection Control & Hospital Epidemiology 42(9): 1160–1162. doi: 10.1017/ice.2020.1221.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798): 270–273. doi: 10.1038/s41586-020-2012-7.
Copyright (c) 2025 Joedhistira Bayu Firmansyah, Musofa Rusli , Juniastuti, Ratna Septyawati
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) Author
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The formal legal aspect of journal publication accessibility refers to Creative Commons Atribution-Share Alike 4.0 (CC BY-SA).
